Bayer’s retinal disease treatment Eylea (aflibercept) is set for an extended treatment interval, a label extension that could give the drug an advantage over rival Roche’s Vabysmo (faricimab). A ...

(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge ...

If approved, Eylea 8 mg would become the only anti-vascular endothelial growth factor (anti-VEGF) treatment in the EU authorized for six-month intervals for both nAMD and DME, according to Bayer ...

Bayer BAYRY announced that the Committee ... Aflibercept’s 2 mg solution injection is approved under the brand name Eylea for the treatment of neovascular (wet) age-related macular degeneration ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

In patients with stable visual outcomes, treatment intervals of up to 5 months may ... Regeneron maintains exclusive rights to Eylea (aflibercept 2 mg) and Eylea HD in the United States. Bayer has ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for Eylea 8 mg (aflibercept 8 mg) for the treatment ...

Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with ...

In these open-label extension studies, 24% of nAMD patients and 28% of DME patients who started with Eylea 8 mg at baseline were on six-month treatment intervals by the end of year three. Eylea 8 mg ...